A recent decision by India’s Patent Office rejecting one of Gilead’s key patents for sofosbuvir is an important step for treatment activists. But Gilead is using every trick in the book to get the decision reversed, including lobbying the Indian Government. Sign our petition today to expand Hep C treatment!
